- Home
- MOBX vs KPTI Comparison
MOBX vs KPTI Comparison
Compare MOBX & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- KPTI
- Stock Information
- Founded
- MOBX 2020
- KPTI 2008
- Country
- MOBX United States
- KPTI United States
- Employees
- MOBX N/A
- KPTI N/A
- Industry
- MOBX
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- MOBX
- KPTI Health Care
- Exchange
- MOBX Nasdaq
- KPTI Nasdaq
- Market Cap
- MOBX 52.0M
- KPTI 44.5M
- IPO Year
- MOBX N/A
- KPTI 2013
- Fundamental
- Price
- MOBX $0.87
- KPTI $5.81
- Analyst Decision
- MOBX
- KPTI Strong Buy
- Analyst Count
- MOBX 0
- KPTI 7
- Target Price
- MOBX N/A
- KPTI $31.71
- AVG Volume (30 Days)
- MOBX 1.9M
- KPTI 286.0K
- Earning Date
- MOBX 08-13-2025
- KPTI 11-04-2025
- Dividend Yield
- MOBX N/A
- KPTI N/A
- EPS Growth
- MOBX N/A
- KPTI N/A
- EPS
- MOBX N/A
- KPTI N/A
- Revenue
- MOBX $10,984,000.00
- KPTI $137,269,000.00
- Revenue This Year
- MOBX N/A
- KPTI $3.40
- Revenue Next Year
- MOBX N/A
- KPTI $9.69
- P/E Ratio
- MOBX N/A
- KPTI N/A
- Revenue Growth
- MOBX 180.13
- KPTI N/A
- 52 Week Low
- MOBX $0.55
- KPTI $3.51
- 52 Week High
- MOBX $2.47
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- MOBX 46.84
- KPTI 45.59
- Support Level
- MOBX $0.90
- KPTI $5.50
- Resistance Level
- MOBX $0.87
- KPTI $6.68
- Average True Range (ATR)
- MOBX 0.10
- KPTI 0.61
- MACD
- MOBX -0.00
- KPTI -0.10
- Stochastic Oscillator
- MOBX 24.91
- KPTI 38.35
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.